Roche Licenses Rona ALK7 RNAi Program

Company Rona Therapeutics; Roche Event Type Licensing Deal Modality RNAi; extrahepatic (adipose-directed) oligonucleotide delivery Asset Investigational ALK7-targeting RNAi candidate (code undisclosed) Target ALK7 (ACVR1C) Disease Area Obesity; metabolic disease Summary Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational ALK7-targeting RNA interference program for…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
GenScript Raises HK$2.33 Billion for AIDD Expansion
TriGemX Raises $94 Million for Phase 3 Migraine Trials